HCC surveillance: minimum standards
Hepatocellular carcinoma (HCC) surveillance is crucial for early detection and improved survival rates, particularly in at-risk populations such as those with chronic liver disease or cirrhosis. To ensure effective surveillance, minimum standards have been established focusing on patient engagement, diagnostic accuracy, and system efficiency.
Target Population: Surveillance should be offered to individuals at high risk of HCC, including those with cirrhosis due to hepatitis B or C, alcohol-related liver disease, non-alcoholic fatty liver disease (NAFLD), and other chronic liver conditions.
Surveillance Intervals: Surveillance should be conducted at 6-month intervals, as evidence shows this frequency balances the benefits of early detection with resource utilization.
Diagnostic Tools: The recommended surveillance method is a combination of abdominal ultrasound and serum alpha-fetoprotein (AFP) testing. Ultrasound is the primary tool, while AFP serves as an adjunct to improve sensitivity. However, AFP alone is not sufficient due to its variability and limited specificity.
Integrated Systems: A robust, digital call-recall system is essential to track eligible patients and ensure timely surveillance. This system should automatically flag missed appointments and facilitate re-engagement.
Patient Engagement: Education and communication are critical to improve adherence. A multifaceted approach, including culturally sensitive materials, personalized reminders, and patient navigation support, can address barriers to participation.
Quality Assurance: Surveillance programs should have mechanisms for regular monitoring, auditing, and feedback to ensure adherence to guidelines and optimize outcomes.
By meeting these minimum standards, healthcare systems can enhance HCC surveillance, improve early diagnosis, and ultimately reduce mortality rates associated with this aggressive cancer.
